T-knife Taps Into Investor Interest in T-Cell Receptor Therapies
Raises $110m In Series B
Executive Summary
The German biotech has raised a significant sum to advance its T-cell therapies for solid tumors developed using its transgenic mouse technology platform.
You may also be interested in...
Anocca To Reach Clinical-Stage With T-Cell Therapies After Series B Injection
Sweden-based Anocca AB will use a just completed $47m Series B financing to advance its industrialized cellular biology platform and pipeline of TCR-T cellular therapies into Phase I/IIa oncology clinical trials, its CEO tells Scrip.
Orphazyme’s Sorry Story Ends In Fire Sale
While Orphazyme's attempts to get approval for arimoclomol failed miserably, new owner KemPharm is confident it can get the oral heat shock protein amplifier across the regulatory finishing line for Neimann-Pick disease type C.
Europe’s Big Pharma Players Begin Tricky 2022 In Style
Big pharma players have embraced a tricky operating environment in 2022 so far, treading a tightrope with political and financial challenges impacting their decision making and threatening to blow them off balance. However, what is not in doubt is the healthy growth experienced by those companies based around mainland Europe and the UK.